Comparison Guide · 15 min
The two most effective GLP-1 medications for weight loss, side by side. Efficacy, side effects, cost, and how to make the decision with your physician — all backed by real clinical trial data.
Tirzepatide tends to produce more average weight loss (≈20% vs. ≈15%) and may have a slightly lower nausea rate. Semaglutide is cheaper, has a longer clinical track record, and is easier to source. The best choice depends on your body, budget, and goals — and it's a decision to make with a physician, not on the internet.
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Drug class | GLP-1 agonist | Dual GLP-1 + GIP agonist |
| Frequency | Weekly injection | Weekly injection |
| Max dose (weight loss) | 2.4 mg | 15 mg |
| Average weight loss in trials | 14.9% at 68 weeks (STEP 1) | 20.9% at 72 weeks (SURMOUNT-1) |
| FDA diabetes approval | 2017 (Ozempic®) | 2022 (Mounjaro®) |
| FDA obesity approval | 2021 (Wegovy®) | 2023 (Zepbound®) |
| Nausea rate (STEP/SURMOUNT) | ~44% | ~30% |
| MTC/MEN2 risk | Black box warning | Black box warning |
| Brand price (uninsured) | $900–$1,300/mo | $1,060–$1,300/mo |
| Compounded price (REMEVi) | $249/mo | $339/mo |
Semaglutide is a GLP-1 receptor agonist (glucagon-like peptide-1). It mimics a gut hormone that regulates appetite, slows gastric emptying, and improves insulin response. FDA-approved in 2017 for type 2 diabetes (Ozempic®) and in 2021 for weight loss (Wegovy®).
Tirzepatide is a dual GLP-1 and GIP receptor agonist (glucose-dependent insulinotropic polypeptide). By activating both receptors simultaneously, it produces a more potent hormonal signal than semaglutide — resulting in greater appetite reduction and better glycemic control. FDA-approved in 2022 for type 2 diabetes (Mounjaro®) and in 2023 for weight loss (Zepbound®).
The pivotal trial for semaglutide was STEP 1 (NEJM 2021): 1,961 adults with obesity received semaglutide 2.4 mg weekly or placebo over 68 weeks. The semaglutide group lost 14.9% of body weight on average, vs. 2.4% on placebo. A third of participants lost more than 20%.
The pivotal trial for tirzepatide was SURMOUNT-1 (NEJM 2022): 2,539 adults with obesity received tirzepatide (5, 10, or 15 mg) or placebo over 72 weeks. The 15 mg group lost 20.9% on average; the 10 mg group, 19.5%; the 5 mg group, 15.0%. More than 50% of participants on higher doses lost more than 20%.
SURMOUNT-5 (2025) was the first direct head-to-head trial between tirzepatide and semaglutide for weight loss. Tirzepatide produced significantly greater weight loss (~47% more weight lost on average). This confirmed what indirect trials had suggested.
Both drugs share the GLP-1 family side-effect profile:
In head-to-head trials, tirzepatide shows slightly less severe nausea, possibly because the GIP component may have centrally-mediated anti-nausea effects. But this varies a lot between patients — some tolerate semaglutide better, others tirzepatide.
Retail prices without insurance are similar for brand versions:
For compounded versions, the difference is more noticeable because tirzepatide's active ingredient is more expensive for compounding pharmacies to source:
The annual difference is ~$1,560. For many patients, that's decisive. For others, the additional weight loss with tirzepatide justifies the cost.
This is a conversation you should have with a licensed physician who knows your full medical history. That said, the following factors usually guide the decision:
In direct and indirect clinical trials, tirzepatide has shown greater average weight loss. SURMOUNT-1 (tirzepatide) reported an average 20.9% body weight loss at 72 weeks on 15 mg weekly. STEP 1 (semaglutide) reported 14.9% at 2.4 mg weekly over 68 weeks. These aren't identical head-to-head trials, but the difference is consistent — and SURMOUNT-5 (2025) confirmed it directly.
Tirzepatide is a dual GLP-1 + GIP agonist — it activates both the GLP-1 receptor (like semaglutide) and the GIP receptor (another incretin hormone). This dual action appears to amplify effects on appetite, gastric emptying, and insulin sensitivity. Semaglutide only targets GLP-1.
Side effects are similar in type (mostly gastrointestinal), but tirzepatide tends to have a slightly lower rate of severe nausea at comparable doses. Both require gradual titration and both can cause pancreatitis, gallbladder issues, and carry the same MTC/MEN2 contraindication.
It depends on several factors a physician should evaluate: your current BMI and target weight, tolerance for gastrointestinal side effects, monthly budget, diabetes or prediabetes history, and personal preferences. Many patients start with semaglutide because of its longer track record and lower cost, and consider switching to tirzepatide if weight loss stalls.
Yes, under medical supervision. Switching typically involves discontinuing one, waiting at least a week (given their long half-lives), and starting the other at the low initial dose with normal titration. They should never be combined — they're in the same functional family and combining them doesn't add benefit but increases side-effect risk.
Brand without insurance: Wegovy® (semaglutide) around $1,300/month; Zepbound® (tirzepatide) around $1,060/month. Compounded (prepared by authorized pharmacies): semaglutide typically $200–$400/month, tirzepatide $300–$500/month. REMEVi offers compounded semaglutide from $249/month and compounded tirzepatide from $339/month, all-inclusive.
Tirzepatide (Mounjaro®) has shown greater hemoglobin A1c reduction in clinical trials compared to semaglutide (Ozempic®). That said, both are extremely effective. For diabetes, the decision also depends on comorbidities, tolerance, and insurance coverage (Ozempic is on more plan formularies currently).
Yes, a few: 1) Lower cost in both compounded and brand forms. 2) Longer clinical track record — semaglutide has been on the market longer and has more long-term safety data. 3) Better availability — some compounding pharmacies have limited access to tirzepatide. 4) Some patients tolerate semaglutide better in terms of side effects.
A licensed bilingual physician reviews your history and recommends the right medication for your individual case.
Start the quiz →Disclaimer: This guide compares two prescription medications. It is not individual medical advice. The decision about any medication should be made with a licensed physician who knows your full medical history.
No insurance required · Cancel anytime